Program
pimurutamab
Also written as “HLX07”, “HLX43+HLX07” and “HLX43 DOSE 2 + HLX10 + HLX07”.
In Fosun Pharma’s pipeline, pimurutamab
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colonic Neoplasms · Nasopharyngeal Carcinoma · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Adenosquamous, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 168 open or running | phase 3since Jan 4, 2026 | Jun 11, 2018 | Jul 28, 2027phase 2 · NCT07358585 |
| Henlixits history only | 10 open or running | phase 1since Dec 27, 2015 | Dec 27, 2015 | none ahead |
- Named in Fosun Pharma’s own pipeline as
HLX07 (pimurutamab)
, phase 2, as of Sep 21, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Fosun Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 11, 2018First study: phase 2 study in Advanced Solid TumorsFirst studyNCT03577704 · 56 enrolled · China
- Dec 9, 2019Named pimurutamabINNProposed as its International Nonproprietary Name in WHO's List 122
- Mar 2, 2020Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT04297995 · 131 enrolled · China
- Jul 20, 2021Phase 2 study in Squamous Non-small-cell Lung CancerNCT04976647 · 156 enrolled · China
- Jan 18, 20222 phase 2 studiesNCT05215925, NCT05221658
- Feb 7, 20223 phase 2 studiesNCT05239650, NCT05238363, NCT05246982
- Mar 7, 2022Phase 2 study in Advanced Hepatocellular CarcinomaNCT05290220 · 60 enrolled
- Apr 26, 2022Phase 1 study in Solid TumorNCT05360368 · 24 enrolled · China
- Apr 26, 2022Phase 2 study in Small Cell Lung CarcinomaNCT05354700 · 20 enrolled · China
- Aug 18, 2022Phase 2 study in Nasopharyngeal Carcinoma by AJCC V8 StageNCT05513573 · 75 enrolled · China
- Feb 27, 2025Phase 2 study in Carcinoma of Head and/or NeckNCT06857279 · 167 planned · China
- Jan 4, 2026Phase 3 study in Squamous NSCLCPhase 3 reachedNCT07318883 · 720 planned · China
- Jan 14, 2026Phase 2 study in Colonic NeoplasmsNCT07358585 · 126 planned · China
- Mar 5, 2026Phase 3 study in Advanced or Metastatic Squamous Non-Small Cell Lung CancerNCT07459751 · 706 planned · China
Ahead
- Jul 28, 2027Primary completion: phase 2 study in Colonic NeoplasmsNCT07358585
- Dec 30, 2027Primary completion: phase 2 study in Carcinoma of Head and/or NeckNCT06857279
- Jan 15, 2030Primary completion: phase 3 study in Advanced or Metastatic Squamous Non-Small Cell Lung CancerNCT07459751
- Jan 2031Primary completion: phase 3 study in Squamous NSCLCNCT07318883
TargetBeta
“pimurutamab”the company's pipeline, read by Claude · source
“A glycoengineered humanized version of the monoclonal antibody of cetuximab, with potential antineoplastic activity. Upon intravenous administration, pimurutamab selectively targets and binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activa…”NCIt, read by Claude
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| befotertinibrule | Betta Pharmaceuticals | phase 3 | 6 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 16 Fosun Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07459751Advanced or Metastatic Squamous Non-Small Cell Lung Cancer · China | 3 | Recruiting | Jan 15, 2030 | 706 |
| NCT07358585Colonic Neoplasms · China | 2 | Not yet recruiting | Jul 28, 2027 | 126 |
| NCT07318883Squamous NSCLC · China | 3 | Not yet recruiting | Jan 2031 | 720 |
| NCT06857279Carcinoma of Head and/or Neck · China | 2 | Recruiting | Dec 30, 2027 | 167 |
| NCT05513573Nasopharyngeal Carcinoma by AJCC V8 Stage · China | 2 | Active, not recruiting | Sep 30, 2024 | 75 |
| NCT05360368Solid Tumor · China | 1 | UNKNOWN | Dec 30, 2023 | 24 |
| NCT05354700Small Cell Lung Carcinoma · China | 2 | UNKNOWN | Mar 29, 2024 | 20 |
| NCT05290220Advanced Hepatocellular Carcinoma | 2 | UNKNOWN | Dec 15, 2023 | 60 |
| NCT05246982Stomach Neoplasms · China | 2 | UNKNOWN | Dec 20, 2023 | 40 |
| NCT05239650CRC | 2 | Not yet recruiting | Oct 15, 2025 | 50 |
| NCT05238363Cutaneous Squamous Cell Carcinoma · China | 2 | UNKNOWN | May 15, 2023 | 20 |
| NCT05221658ESCC or Esophageal Adenosquamous Carcinoma · China | 2 | Recruiting | Jun 30, 2024 | 60 |
| NCT05215925HLX07, nsqNSCLC, High EGFR Expression · China | 2 | UNKNOWN | Jul 15, 2023 | 60 |
| NCT04976647Squamous Non-small-cell Lung Cancer · China | 2 | UNKNOWN | Jan 30, 2023 | 156 |
| NCT04297995Squamous Cell Carcinoma of Head and Neck · China | 2 | Active, not recruiting | May 30, 2024 | 131 |
| NCT03577704Advanced Solid Tumors · China | 2 | Completed | Sep 30, 2022 | 56 |
How it is read
Names in the registry
- “HLX07”, 12 entries
- “HLX43+HLX07”, 1 entry
- “HLX43 DOSE 2 + HLX10 + HLX07”, 1 entry
- “HLX43 DOSE 3 + HLX10 + HLX07”, 1 entry
- “HLX43 dose 1 + HLX07”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Colonic Neoplasms, 1 study
- Nasopharyngeal Carcinoma, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Carcinoma, Adenosquamous, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.